	US 12,491,242 B2
	Recombinant viruses and the uses thereof
Kenta Sasaki, Yokohama (JP); and Jina Lee, Yokohama (JP)
Assigned to CEVA SANTE ANIMALE S.A., Libourne (FR)
Appl. No. 17/417,455
Filed by Ceva Sante Animale, Libourne (FR)
PCT Filed Dec. 26, 2019, PCT No. PCT/EP2019/087042 § 371(c)(1), (2) Date Jun. 23, 2021, PCT Pub. No. WO2020/136220, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 18306852 (EP), filed on Dec. 27, 2018.
Prior Publication US 2022/0062411 A1, Mar. 3, 2022
Int. Cl. A61K 39/255 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/255 (2013.01) [C12N 15/1131 (2013.01); C12N 15/86 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/552 (2013.01); C12N 2710/16334 (2013.01)]

25 Claims

1. A recombinant Marek's Disease Virus of serotype 1 (rMDV1) comprising a recombinant nucleotide sequence in its genome, wherein said recombinant nucleotide sequence is located in the MDV086.6 (SORF1) locus of the genome, and wherein said rMDV1 retains the coding sequence of SORF2 and US1.